Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more
Sangamo Therapeutics Inc (SGMO) - Net Assets
Latest net assets as of September 2025: $6.24 Million USD
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has net assets worth $6.24 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($88.64 Million) and total liabilities ($82.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.24 Million |
| % of Total Assets | 7.04% |
| Annual Growth Rate | 15.19% |
| 5-Year Change | -95.42% |
| 10-Year Change | -88.17% |
| Growth Volatility | 287.94 |
Sangamo Therapeutics Inc - Net Assets Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sangamo Therapeutics Inc (1996–2024)
The table below shows the annual net assets of Sangamo Therapeutics Inc from 1996 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.77 Million | -72.53% |
| 2023-12-31 | $82.89 Million | -71.90% |
| 2022-12-31 | $294.96 Million | -21.42% |
| 2021-12-31 | $375.34 Million | -24.53% |
| 2020-12-31 | $497.37 Million | +14.93% |
| 2019-12-31 | $432.74 Million | +18.07% |
| 2018-12-31 | $366.52 Million | +95.06% |
| 2017-12-31 | $187.90 Million | +37.96% |
| 2016-12-31 | $136.19 Million | -29.23% |
| 2015-12-31 | $192.44 Million | -6.87% |
| 2014-12-31 | $206.63 Million | +69.77% |
| 2013-12-31 | $121.71 Million | +87.55% |
| 2012-12-31 | $64.90 Million | -19.01% |
| 2011-12-31 | $80.13 Million | +43.33% |
| 2010-12-31 | $55.91 Million | -22.12% |
| 2009-12-31 | $71.78 Million | +29.58% |
| 2008-12-31 | $55.40 Million | -23.19% |
| 2007-12-31 | $72.12 Million | +48.08% |
| 2006-12-31 | $48.70 Million | +28.80% |
| 2005-12-31 | $37.81 Million | +16.79% |
| 2004-12-31 | $32.38 Million | -27.50% |
| 2003-12-31 | $44.66 Million | -17.67% |
| 2002-12-31 | $54.25 Million | -34.13% |
| 2001-12-31 | $82.35 Million | +23.11% |
| 2000-12-31 | $66.89 Million | +746.71% |
| 1999-12-31 | $7.90 Million | +132.08% |
| 1998-12-31 | $3.40 Million | -46.89% |
| 1997-12-31 | $6.41 Million | +1376.73% |
| 1996-12-31 | $434.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sangamo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 150399200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.13 Million | 9.35% |
| Other Comprehensive Income | $-7.53 Million | -33.07% |
| Other Components | $1.53 Billion | 6730.30% |
| Total Equity | $22.77 Million | 100.00% |
Sangamo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Sangamo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
United Pharm
KO:033270
|
$125.34 Million |
|
West Coast Paper Mills Limited
NSE:WSTCSTPAPR
|
$125.35 Million |
|
DOHOME
BK:DOHOME-R
|
$125.36 Million |
|
StealthGas Inc
NASDAQ:GASS
|
$125.36 Million |
|
Nantong Xingqiu Graphite Co. Ltd. A
SHG:688633
|
$125.29 Million |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
$125.26 Million |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
$125.22 Million |
|
Cornerstone OnDemand Inc
F:8CO
|
$125.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sangamo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 82,887,000 to 22,770,000, a change of -60,117,000 (-72.5%).
- Net loss of 97,941,000 reduced equity.
- Share repurchases of 290,000 reduced equity.
- New share issuances of 28,991,000 increased equity.
- Other comprehensive income decreased equity by 2,935,000.
- Other factors increased equity by 12,058,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-97.94 Million | -430.13% |
| Share Repurchases | $290.00K | -1.27% |
| Share Issuances | $28.99 Million | +127.32% |
| Other Comprehensive Income | $-2.94 Million | -12.89% |
| Other Changes | $12.06 Million | +52.96% |
| Total Change | $- | -72.53% |
Book Value vs Market Value Analysis
This analysis compares Sangamo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.50x to 3.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $0.08 | $0.38 | x |
| 1997-12-31 | $1.17 | $0.38 | x |
| 1998-12-31 | $0.58 | $0.38 | x |
| 1999-12-31 | $1.31 | $0.38 | x |
| 2000-12-31 | $3.85 | $0.38 | x |
| 2001-12-31 | $3.56 | $0.38 | x |
| 2002-12-31 | $2.21 | $0.38 | x |
| 2003-12-31 | $1.80 | $0.38 | x |
| 2004-12-31 | $1.29 | $0.38 | x |
| 2005-12-31 | $1.46 | $0.38 | x |
| 2006-12-31 | $1.50 | $0.38 | x |
| 2007-12-31 | $1.93 | $0.38 | x |
| 2008-12-31 | $1.36 | $0.38 | x |
| 2009-12-31 | $1.71 | $0.38 | x |
| 2010-12-31 | $1.24 | $0.38 | x |
| 2011-12-31 | $1.59 | $0.38 | x |
| 2012-12-31 | $1.23 | $0.38 | x |
| 2013-12-31 | $2.17 | $0.38 | x |
| 2014-12-31 | $3.08 | $0.38 | x |
| 2015-12-31 | $2.76 | $0.38 | x |
| 2016-12-31 | $1.93 | $0.38 | x |
| 2017-12-31 | $2.41 | $0.38 | x |
| 2018-12-31 | $3.78 | $0.38 | x |
| 2019-12-31 | $3.86 | $0.38 | x |
| 2020-12-31 | $3.71 | $0.38 | x |
| 2021-12-31 | $2.60 | $0.38 | x |
| 2022-12-31 | $1.91 | $0.38 | x |
| 2023-12-31 | $0.48 | $0.38 | x |
| 2024-12-31 | $0.11 | $0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sangamo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -430.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -169.45%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 4.46x
- Recent ROE (-430.13%) is below the historical average (-60.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -70.97% | -48.73% | 1.17x | 1.24x | $-351.40K |
| 1997 | -21.84% | -121.53% | 0.17x | 1.08x | $-2.04 Million |
| 1998 | -96.50% | -161.19% | 0.51x | 1.18x | $-3.63 Million |
| 1999 | -48.10% | -172.73% | 0.24x | 1.16x | $-4.59 Million |
| 2000 | -13.55% | -264.08% | 0.05x | 1.03x | $-15.76 Million |
| 2001 | -30.66% | -516.87% | 0.06x | 1.03x | $-33.48 Million |
| 2002 | -54.87% | -685.33% | 0.08x | 1.04x | $-35.19 Million |
| 2003 | -23.36% | -404.54% | 0.06x | 1.04x | $-14.90 Million |
| 2004 | -42.68% | -1050.80% | 0.04x | 1.07x | $-17.06 Million |
| 2005 | -35.15% | -535.14% | 0.05x | 1.30x | $-17.07 Million |
| 2006 | -36.68% | -226.56% | 0.14x | 1.15x | $-22.73 Million |
| 2007 | -29.78% | -236.10% | 0.11x | 1.16x | $-28.69 Million |
| 2008 | -43.87% | -150.14% | 0.24x | 1.22x | $-29.84 Million |
| 2009 | -25.89% | -83.77% | 0.25x | 1.22x | $-25.77 Million |
| 2010 | -44.46% | -119.46% | 0.33x | 1.13x | $-30.44 Million |
| 2011 | -44.61% | -346.45% | 0.12x | 1.09x | $-43.76 Million |
| 2012 | -34.31% | -102.81% | 0.26x | 1.27x | $-28.75 Million |
| 2013 | -21.87% | -110.32% | 0.17x | 1.16x | $-38.80 Million |
| 2014 | -12.78% | -57.59% | 0.19x | 1.18x | $-47.08 Million |
| 2015 | -21.15% | -102.94% | 0.18x | 1.13x | $-59.95 Million |
| 2016 | -52.61% | -369.58% | 0.12x | 1.16x | $-85.28 Million |
| 2017 | -29.04% | -149.23% | 0.13x | 1.53x | $-73.36 Million |
| 2018 | -18.64% | -80.91% | 0.14x | 1.61x | $-104.99 Million |
| 2019 | -17.53% | -74.02% | 0.16x | 1.47x | $-119.07 Million |
| 2020 | -24.31% | -102.48% | 0.13x | 1.88x | $-170.95 Million |
| 2021 | -47.50% | -161.06% | 0.15x | 1.92x | $-215.83 Million |
| 2022 | -65.19% | -172.76% | 0.20x | 1.91x | $-221.77 Million |
| 2023 | -311.06% | -146.30% | 1.07x | 1.99x | $-266.12 Million |
| 2024 | -430.13% | -169.45% | 0.57x | 4.46x | $-100.22 Million |
Industry Comparison
This section compares Sangamo Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sangamo Therapeutics Inc (SGMO) | $6.24 Million | -70.97% | 13.20x | $125.33 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |